Skip to main content
  1. Right Decisions
  2. Neurology pathways
  3. Back
  4. Headache
  5. 7. Medication Overuse Guidance
Announcements and latest updates

Right Decision Service newsletter: September 2024

Welcome to the Right Decision Service (RDS) newsletter for September 2024.

1.Business case for permanent provision of the Right Decision Service from April 2025 onwards

This business case has now been endorsed by the HIS Board and will shortly be submitted to Scottish Government.

2. Management of RDS support tickets

To balance increasing demand with available capacity and financial resource, the RDS team and Tactuum are now working together to  implement closer management of support tickets. As a key part of this, we want to ensure clear, timely and consistent communication with yourselves as requesters.  

Editors will now start seeing new messages come through in response to support ticket requests which reflect this tightening up and improvement of our processes.

Key points to note are:

2.1 Issues confirmed by the RDS and Tactuum teams as meeting the critical/urgent and high priority criteria will continue to be prioritised and dealt with immediately.

Critical/urgent issues are defined as:

  1. The Service as a whole is not operational for multiple users. OR
  2. Multiple core functions of the Service are not operational for multiple users.

Example – RDS website outage.

Please remember to email ann.wales3@nhs.scot and his.decisionsupport@nhs.scot with any critical/urgent issues in addition to raising a support ticket.

High priority issues are defined as:

  1. A single core function of the Service is not operational for multiple users. OR:
  2. Multiple non-core functions of the Service are not operational for multiple users.

Example – Build to app not working.

2.2 Support requests that are outwith the warranty period of 12 weeks since the software was originally developed will not be automatically addressed by Tactuum. The RDS team will consider these requests for costed development work and will obtain estimate of effort and cost from Tactuum for priority issues.

2.3 Support tickets for technical issues that are not classified as bugs will not be automatically addressed by Tactuum. The definition of a bug is ‘a defect in the software that is at variance with documented user requirements.’  Issues that are not bugs will also be considered for costed development work.

The majority of issues currently in support tickets fall into category 2 or 3 above, or both.

2.4 Non-urgent requests that require a deployment (i.e a new release of RDS) will normally be factored into the next scheduled release (currently end of Nov 2024 and end of Feb 2025) unless by special agreement with the RDS team.

Please note that we plan to move in the new year to a new system whereby requests all come to an RDS support portal in the first instance and are triaged from there to Tactuum when appropriate.

We will be organising a webinar in a few weeks’ time to take you through the details of the current support processes and criteria.

3. Next scheduled deployment.

The next scheduled RDS deployment will take place at the end of November 2024.  We are reviewing all outstanding support tickets and feature requests along with estimates of effort and cost to determine which items will be included in this deployment.

We will update you on this in the next newsletter and in the planned webinar about support ticket processes.

4. Contingency arrangements for RDS

Many thanks to those of you who attended our recent webinar on the contingency arrangements being put in place to prevent future RDS outages as far as possible and minimise impact if they do occur.  Please contact ann.wales3@nhs.scot if you would like a copy of the slides from this session.

5. Transfer of CKP pathways to RDS

The NES clinical knowledge pathway (CKP) publisher is now retired and the majority of pathways supported by this tool have been transferred to the RDS. Examples include:

NHS Lothian musculoskeletal pathways

NHS Fife rehabilitation musculoskeletal pathways

NHS Tayside paediatric pathways

6. Other new RDS toolkits

Include:

Focus on frailty (from HIS Frailty improvement programme)

NHS GGC Money advice and support

If you would like to promote one of your new toolkits through this newsletter, please contact ann.wales3@nhs.scot

To go live imminently:

  • Focus on dementia
  • NHS Lothian infectious diseases toolkit
  • Dumfries and Galloway Adult Support and Protection procedures
  • SIGN guideline – Prevention and remission of type 2 diabetes

 

7. Evaluation projects

We have recently analysed the results of a survey of users of the Scottish Palliative Care Guidelines toolkit.  Key findings from 61 respondents include:

  • Most respondents (64%) are frequent users of the toolkit, using it either daily or weekly. A further 25% use it once or twice per month.
  • 5% of respondents use the toolkit to deliver direct patient care and 82% use it for learning
  • Impact on practice and decision-making was rated as very high, with 80% of respondents rating these at a 4-5 on a 5 point scale.
  • Impact on time saving was also high, with 74% of respondents rating it from 3-5.
  • 74% also reported that the toolkit improved their knowledge and skills, rating these at 4-5 on the Likert scale

Key strengths identified included:

  • The information is useful, succinct, and easy to understand (31%).
  • Coverage is comprehensive (15%)
  • All information is readily accessible in one place and users value the offline access via mobile app (15%)
  • Information is reliable, evidence-based and up to date (13%)

Users highlighted key areas for improvement in terms of navigation and search functionality. The survey was very valuable in enabling us to uncover the specific issues affecting the user experience. Many of these can be addressed through content management approaches. The issues identified with search results echo other user feedback, and we are costing improvements with a view to implementation in the next RDS deployment.

8.RDS High risk prescribing (polypharmacy) decision support embedded in Vision and EMIS primary care E H R systems

This decision support software, sponsored by Scottish Government Effective Prescribing and Therapeutics Division,  is now available for all primary care clinicians across NHS Tayside. Board-wide implementation is also planned for NHS Lothian, and NHS GGC, NHS Ayrshire and Arran and NHS Dumfries and Galloway have initial pilots in progress. The University of Dundee has been commissioned to evaluate impact of this decision support software on prescribing practice.

9. Video tutorials for RDS editors

Ten bite-size (5 mins or less) video tutorials for RDS editors are now available in the “Resources for providers of RDS tools” section of the RDS.  These cover core functionality including Save and preview, content page and media management, password management and much more.

10. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Wednesday 23rd October 4-5 pm
  • Tuesday 29th October 11 am -12 pm

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

 

Warning

Background

Medication overuse headache (MOH) is defined as headache occurring on 15 or more days per month in a patient with a pre-existing primary headache and developing as a consequence of regular overuse of acute or symptomatic medication for 3 months. Not all patients taking frequent acute medication for the management of primary headache have MOH. MOH can develop in patients taking medication for other painful conditions. 

 

MOH most commonly occurs as a complication of the management of migraine, although it can occur in any primary headache disorder. It rarely occurs in cluster headache and if it does the patient usually also has migraine.  

 

Any acute or symptomatic medication taken for the management of primary headache can result in MOH, although the highest risk is with triptans and opioids. 

  • Simple analgesics (Aspirin, NSAIDs, Paracetamol) > 15 days per month 
  • Triptans, opioids and combination analgesics > 10 days per month 

Medication Overuse Headache: Prevention

When prescribing acute treatment in primary headache patients should be warned about the risk of medication overuse headache. This is particularly important in patients with migraine. In general the use of simple analgesics and triptans should be restricted to 8-10 days per month. The use of combination analgesics and opioids should be avoided. Preventative treatment should be considered early in patients with frequent headache.

 

In cluster headache, because the headaches are so severe and the risk of MOH very low, patients should be allowed to use up to 2 doses of a triptan per day (subcutaneous sumatriptan or nasal sumatriptan/ zolmatriptan). 

Medication Overuse Headache Investigation

Before diagnosing MOH it is important to consider other secondary causes of chronic daily headache and investigate appropriately. 

Medication Overuse Headache: Treatment Strategies

1. Explanation: 

Adequate explanation is the key to managing MOH. The patient should be made aware that frequent use of acute medication “winds up” the migraine process making it more likely to happen and results in chronic headache. MOH is a recognised complication of the management of headache and rationalising/stopping medication can improve headache. Patients should be aware that headache can worsen before it improves (re-bound headache) and that this can last for days/weeks. Headache may still require appropriate management with acute and preventative treatment following medication withdrawal. Resuming frequent acute medication use is likely to result in re-emergence of MOH. 

2. Medication withdrawal: 

Medication withdrawal is the recommended strategy in patients with MOH. For simple analgesics and triptans abrupt withdrawal is preferable. For combination analgesics (particularly those containing high dose codeine) and opioids gradual withdrawal is recommended. The patient should be warned to expect withdrawal headaches. Other symptoms commonly encountered include: nausea, sleep disturbance and anxiety. Anti-emetics should be considered during the withdrawal phase and patients advised to keep adequately hydrated. Patients overusing triptans can be expected to improve over 7-10 days and those overusing simple analgesics over 2-3 weeks, but improvement can take a few months. For those who cannot manage abrupt withdrawal rationalising acute medication to 2 days per week can be helpful.  

Because medication withdrawal usually results in improvement rather than cessation of headaches adding in or adjusting preventative medication at the same time as initiating withdrawal should be considered. 

3. Preventative treatment: 

The effectiveness of most oral preventative treatments is reduced in MOH and if a preventative treatment is started this should be combined with rationalisation of the overused medication. Topiramate, Botulinum Toxin A and CGRP monoclonal antibodies are less likely to be affected by medication overuse. 

Referral criteria to secondary care (Medication Overuse Headache)

In patients with Medication Overuse Headache an adequate explanation, trial of medication withdrawal and consideration of starting prophylactic treatment should be undertaken prior to referral into secondary care. 

References and further resources

Wakerly, B. Medication Overuse Headache. Practical Neurology. 2019;19:399-403 

SIGN 155 Pharmacological management of migraine – updated March 2023; includes clinician and patient guidelines 

url: Pharmacological management of migraine (sign.ac.uk)  

British Association for the Study of Headache (BASH) National Management System 2019; includes clinician and patient portals 

url: Headache UK 

Editorial Information

Last reviewed: 11/10/2023

Next review date: 01/04/2025